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Abstract
Objective
To evaluate if the timing of appearance with respect to disease onset may influence the arthritis presentation pattern in 
antisynthetase syndrome (ASSD).
Methods
The patients were selected from a retrospective large international cohort of ASSD patients regularly followed-up in 
centres referring to AENEAS collaborative group. Patients were eligible if they had an antisynthetase antibody testing 
positive in at least two determinations along with arthritis occurring either at ASSD onset (Group 1) or during the 
course of the disease (Group 2).
Results
445 (70%; 334 females, 110 males, 1 transsexual) out of the 636 ASSD we collected had arthritis, in the majority of cases 
(367, 83%) from disease onset (Group 1). Patients belonging to Group 1 with respect to Group 2 had an arthritis more 
commonly polyarticular and symmetrical (p=0.015), IgM-Rheumatoid factor positive (p=0.035), erosions at hands and 
feet plain x-rays (p=0.036) and more commonly satisfying the 1987 revised classification criteria for rheumatoid arthritis 
(RA) (p=0.004). Features such as Raynaud’s phenomenon, mechanic’s hands and fever (e.g. accompanying findings) 
were more frequently reported in Group 2 (p=0.005).
Conclusion
In ASSD, the timing of appearance with respect to disease onset influences arthritis characteristics. In particular, 
RA features are more common when arthritis occurs from ASSD onset, suggesting an overlap between RA and ASSD in 
these patients. When arthritis appears during the follow-up, it is very close to a connective tissue disease-related arthritis. 
Also, the different prevalence of accompanying features between these two groups is in line with this possibility.
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Introduction
Arthritis is a well-established feature 
of antisynthetase syndrome (ASSD), 
reported in up to 80% of cases and 
representing, together with myositis 
and interstitial lung disease (ILD), the 
classic clinical triad of the disease (1-
4). In ASSD, arthritis may appear ei-
ther at disease onset (5, 6) or during 
the follow-up (4), with heterogeneous 
characteristics from both the clinical, 
laboratory and radiology point of view 
(4, 6-8). The differential diagnosis of 
rheumatoid arthritis (RA) is frequently 
challenging, especially at disease on-
set (4) and in patients presenting with 
an isolated arthritis (5), who are at in-
creased risk for the subsequent occur-
rence of lacking triad features (5, 9).
Despite better awareness, several ques-
tions on arthritis still remain unanswered 
in this setting. The aim of this study is to 
evaluate in a large cohort of patients if 
characteristics of arthritis occurring af-
ter ASSD onset (e.g. in the follow-up of 
these patients) are different from those 
of arthritis occurring at disease onset.
Methods
Patients 
Patients were selected from a retro-
spective large cohort of ASSD patients 
regularly followed-up at 48 Rheuma-
tology, Pneumology and Neurology 
centres from Italy (n=28), Spain (n=9), 
Germany (n=6), Portugal (n=1), Nor-
way (n=1), Sweden (1), USA (n=1) and 
Mexico (n=1). Patients were eligible 
if they had an antisynthetase antibody 
testing positive in at least two determi-
nations along with arthritis (observed 
by an experienced rheumatologist in all 
cases) at the onset or during the disease 
course and if they signed the informed 
consent as approved by the local Insti-
tutional Ethics Board. Type and char-
acteristics of arthritis and other clinical 
features, laboratory and instrumental in-
vestigations, at onset and during follow-
up, were then evaluated. As previously 
described (4, 5), arthritis occurrence 
(joint swelling and tenderness required) 
and its presentation pattern (e.g. sym-
metrical polyarthritis, oligoarticular/
asymmetrical arthritis) were clinically 
assessed.  The majority of patients had 
hand and feet plain x-rays. ILD was 
defined instrumentally by a restrictive 
pulmonary function test (PFT) pattern 
(FVC ≤80%, FEV1/FVC ≥70%, de-
creased or normal FEV1, and/or <20% 
reduction in DLCO), and/or by signs 
of alveolitis/fibrosis on high-resolution 
computed tomography (HRCT). PFTs 
were performed at baseline as part of 
the assessment of lung involvement 
in an early arthritis/connective tissue 
disease and then regularly during the 
follow-up. Lung HRCT was performed 
in the case of respiratory symptoms, 
altered PFTs and when antisynthetase 
antibodies were found positive. Patients 
with muscle enzyme elevation (creati-
nine phosphokinase and/or aldolase) 
and the presence of typical electromyo-
graphy alterations and/or compatible 
muscle biopsy findings and/or compat-
ible muscle magnetic resonance, were 
considered as having muscle involve-
ment. Muscle enzymes were routinely 
performed at baseline and during the 
follow-up in all patients, regardless of 
the occurrence of muscle symptoms.
The onset of ASSD was considered as 
the time of the first pulmonary, mus-
cular or joint symptom or sign. The 
onset of clinical features was consid-
ered concurrent in cases of less than 3 
months of delay after the presentation 
of manifestations. Patients included in 
this study were divided into 2 clinical 
groups: Group 1 – arthritis at disease 
onset; Group 2 – arthritis after disease 
onset (ex-novo arthritis, i.e. more than 
3 months after the onset of the first non-
arthritis triad finding).
Patients were also assessed for the oc-
currence of accompanying features and 
related time of appearance. Fever was 
considered related to ASSD in case of a 
body temperature ≥38°C for more than 
10 days without evidence of other pos-
sible causes. Mechanic’s hands were 
defined as the occurrence of a thick-
ened, hyperkeratotic, and fissured as-
pect of the radial sides of the fingers of 
the hands, in absence of any other pos-
sible explanations. Raynaud’s phenom-
enon was defined as the occurrence of 
a transient finger ischaemia after cold 
exposure, confirmed by a clinician. 
Autoantibody profile 
Autoantibodies were considered posi-
46 Clinical and Experimental Rheumatology 2018
Arthritis subsets in antisynthetase syndrome / M.A. González-Gay et al.
tive after two testing confirmations 
along with at least one positivity ob-
tained in the leading reference/tertiary 
centre. In leading centres, besides 
antisynthetase antibodies, other addi-
tional anti-extractable nuclear antigen 
specificities and IgM-RF and ACPA 
were tested by well-validated methods 
(Appendix).
Statistical analysis 
Descriptive data were reported or con-
sidered as absolute and relative fre-
quencies, mean and standard deviation, 
median and interquartile range (IQR) 
based on the type of the variable dis-
tribution. Comparison between groups 
was firstly tested by chi-square test, t-
test or Mann-Whitney test, based on the 
variable type and distribution. Analyses 
were performed using STATA software 
package (2009, release 11; StataCorp, 
TX, USA).
Results
In our cohort of 636 ASSD, 445 patients 
(70%; 334 females, 110 males, 1 trans-
sexual) had arthritis. In these patients, 
the median (IQR) age at disease onset 
was 51 (41–60) years, the diagnostic de-
lay was 7 (2–23) months and the dura-
tion of follow-up 79 (36–149) months.
Anti-Jo-1 antibodies were positive 
in 366 (82%) patients, non-anti Jo-1 
antibodies in 79 (18%). Within non- 
anti-Jo-1 positive patients, 33 (42%) 
were anti-PL-7 positive, 29 (37%) anti-
PL-12, 9 (11%) anti-EJ and 4 (5%) anti- 
OJ. Also, 4 patients (5%) had a double 
positivity (1 OJ/EJ and 3 PL-7/PL-12). 
Anti-Jo-1 and non-anti-Jo-1 positive pa-
tients were equally distributed between 
the two clinical groups (p=0.489). In 
particular, Group 1 included 303 (83%) 
anti-Jo-1 and 63 (17%) non-anti-Jo-1 
positive patients, Group 2, 62 (79%) 
anti-Jo-1 and 16 (21%) non-anti-Jo-1 
positive patients. 
Clinical, laboratory and radiologic find-
ings of all patients are shown in table 1. 
Whereas the 1987 revised ACR classi-
fication criteria for RA (10) were tested 
in the majority of patients, we could 
test only 78 (18%) for the new 2010 
ACR/EULAR classification criteria for 
RA (11), reason that lead us to not in-
clude the obtained result in the study. 
Even if this study was not aimed at 
comparing the inter-centre variability, 
arthritis characteristics were equally 
distributed between the different cen-
tres involved and between different re-
ferral areas (data not shown). Regard-
ing treatments, the majority of group 2 
patients were on immunosuppressants 
when arthritis appeared. All 78 patients 
(100%) were on low dose prednisone 
(< 5mg/day), 35 (45%) on azathioprine, 
12 (15%) on mycophenolate mofetil, 8 
(10%) on cyclosporine, 4 (5%) on cyclo-
phosphamide and 1 (1%) on hydroxy-
chloroquine. 
Figure 1 shows the cluster of triad find-
ings presented at disease onset in the 2 
Groups. 
Discussion
To date, this is the largest study ever to 
address arthritis assessment in ASSD, 
and the first to include a large number 
of non-anti-Jo-1 positive patients. Our 
findings indicate that arthritis in ASSD 
occurs mainly at disease onset and to a 
lesser extent during the follow-up. Fur-
thermore, we found that arthritis char-
acteristics are heterogeneous within the 
syndrome and influenced by its timing 
of onset. In particular, RA-like clinical, 
laboratory and radiologic features are 
Table I. Main demographics and clinical characteristics of patients according to cluster and 
timing of arthritis appearance with respect to other classic triad findings. If not otherwise 
stated, percentage are calculated according to the number of patients with available infor-
mation within the group.
 Group 1: Group 2: p-value
 arthritis at arthritis after 
 disease onset disease onset
  (ex novo arthritis)  
Number of patients (% of total) 367 (83) 78 (17) –
Median age in years at disease onset (IQR) 51 (41-60) 53 (39-61) 0.940
̭
Median diagnostic delay in months (IQR) 6 (2-27) 9 (3-18) 0.107**
Median follow-up in months (IQR) 74 (32-143) 95 (48-178) 0.038**
Females (%) 272 (74) 62 (79) 0.337
Males (%) 94 (26)* 16 (21)
Anti Jo-1 positive (%) 304 (83) 62 (79) 0.483
Non-anti JO-1 positive (%) 63 (17) 16 (21)
Anti-Ro antibodies positive (%) 200 (56) 41 (53) 0.544
Anti-RO antibodies negative (%) 155 (44) 37 (47)
Symmetrical polyarthritis (%) 258 (71) 43 (57) 0.015
Oligoarticular/asymmetrical arthritis (%) 106 (29) 33 (43)
IgM-RF positive (%) 94 (27) 11 (15 0.035
IgM-RF) negative (%) 257 (73) 62 (85)
ACPA positive (%) 33 (11) 5 (8) 0.575
ACPA negative (%) 274 (89) 55 (92)
Patients with x-rays joint erosions (%) 51 (16) 4 (6) 0.036
Patients without x-rays joint erosions (%) 273 (84) 63 (94)
Patients satisfying the 1987 revised ACR 241 (69) 37 (51) 0.004
   classification criteria for RA (%)
Patients NOT satisfying the 1987 revised  109 (31) 35 (49)
   ACR classification criteria for RA (%)
Fever (%)§ 91 (26) 25 (33) 0.211
No fever (%)§ 261 (74) 51 (67)
Raynaud’s phenomenon (%)§ 95 (27) 33 (43) 0.007
No Raynaud’s phenomenon (%)§ 254 (73) 44 (57)
Mechanic’s hands (%)§ 91 (26) 27 (36) 0.082
No Mechanic’s hands (%)§ 258 (74) 48 (64)
Accompanying features (%)§ 183 (56) 56 (74) 0.005
No accompanying findings (%)§ 144 (44) 20 (26)
RF: Rheumatoid factor; ACPA: anticyclic citrulinated peptide antibodies; ILD: interstitial lung disease.
*plus one transexual. §number of accompanying findings ever presented, concomitantly or before arthri-
tis occurrence. Median time from disease to arthritis onset in group 2 (interquartile range): 20 months 
(10-46 months).
Statistical analysis: ̭Independent sample t-test, **Welch-test. Other: Chi square test.
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more likely observed in patients pre-
senting arthritis from disease onset and 
to a lesser extent in those presenting 
with an ex-novo arthritis during the fol-
low-up. Conversely, we first observed 
that ASSD accompanying findings (e.g. 
fever, Raynaud’s phenomenon and me-
chanic’s hands) are significantly less 
frequent in the clinical Group 1 (arthri-
tis at disease onset) when compared to 
Group 2 (arthritis after disease onset 
-ex-novo arthritis). 
We have recently published a study fo-
cused on the evolution of the concept of 
articular involvement in ASSD (5). In 
this paper, we have shown how this con-
cept steadily changed over time, from 
the simple term of polyarthralgia re-
ported in the first studies, to that of sym-
metrical polyarthritis described in the 
last ones. Furthermore, we showed that 
the overlapping aspects between ASSD 
and RA are common in anti-Jo-1 posi-
tive patients presenting with arthritis 
from disease onset in general and with 
an isolated arthritis in particular (4, 5).
At that time, due to the limited number of 
patients developing an ex-novo arthritis 
during the follow-up, we left a relevant 
question unanswered: is arthritis pheno-
type different in patients in whom joint 
involvement appears ex-novo during the 
follow-up? With the increased number 
of centres participating in the AENEAS 
collaborative group, in the present study 
we have reached a number of patients 
that may be large enough to answer this 
question. Furthermore, we enlarged the 
spectrum of analysis by including also a 
relevant number of patients with other 
antisyntethase antibodies specificities. 
First of all, in this study we confirmed 
that it is often difficult to perform a dif-
ferential diagnosis between ASSD and 
RA at disease onset because of several 
clinical, laboratory and radiology simi-
larities. However, the most interesting 
results we disclosed was that ex-novo 
arthritis is more frequently oligoarticu-
lar and asymmetrical with respect to that 
appearing at disease onset. Conversely, 
IgM RF positivity and the radiographic 
evidence of joint erosions were more 
commonly observed in Group 1 with 
respect to Group 2. Furthermore, the 
1987 ACR revised classification criteria 
for RA were less frequently satisfied in 
patients from Group 2 when compared 
to Group 1. Unfortunately, we were able 
to test only a limited number of patients 
with the 2010 new classification criteria 
for RA, without the possibility of draw-
ing conclusions. From the serological 
point of view, anti-Ro antibodies were 
equally distributed among groups, thus 
without other implications to that of po-
tential ASSD markers, at least for arthri-
tis aspects.
If we consider the treatments ongoing 
when arthritis appeared, in the majority 
of cases, the drugs used are not consid-
ered effective from the articular point 
of view along the entire spectrum of 
rheumatic conditions. We may suppose 
that the influence of these treatments 
Fig. 1. Cluster of triad findings in different groups. Inner circles: Group 1, triad findings occurring 
concomitantly to arthritis at disease onset. Group 2, triad findings presented before the appearance of 
arthritis.  MYO: myositis; ILD: interstitial lung disease.
Appendix
List of kits/methodologies used
Anti synthetase antibodies
• INNO-LIA, Immunogenetics Ghent, Belgium
• EliA Jo-1, Phadia, Freiburg, Germany
• ELiA CTD screen, Phadia, Freiburg, Germany
• Zenit RA Jo-1, Menarini Diagnostic, Firenze, Italy
• QUANTA Flash Jo-1, Inova Diagnostics, Werfen Groupe San Diego, USA
• ENA-abs, Euroimmun, Lübeck, Germany
• Counterimmunoelectrophoresis, Bunn CC, Gharavi AE, Hughes GRV. J Clin Lab Immunol 
1982; 8: 13-17. 
• Dot Blot Miositis/Esclero Palex Medical, Barcelona, Spain
• ELISA ORG 514, ORGENTEC, Mainz, Germany
• Myositis Profile Euroline Blot test kit, Euroimmun, Lübeck, Germany
• DotDiver ANAcyto 10, GA Generic Assays GmbH, Berlin, Germany
• MYOSITIS PROFILE - 12 Ag, AL AD-MYOS12D ALIFAX Srl, Padua, Italy BD
Anticyclic citrullinated peptide antibodies
• Aeskulisa 3166 CCP, Aesku.system GmbH & Co, Wendelsheim, Germany
• Anti-CCP EDIA, Eurodiagnostica, Malmoe, Sweden
• Quanta Flash (CIA)  CCP3, INOVA Diagnostics a Werfen Company, San Diego
• Home-made ELISA, Anzilotti C et al. Antibodies to viral citrullinated peptide in 
      rheumatoid arthritis. J Rheumatol 2006; 33: 647-51. 
• Zenit RA CCP, Menarini Diagnostic, Firenze, Italy
• EliA CCP, Phadia, Freiburg, Germany (Torino)
• Anti-CCP Ab’s, Roche Diagnostics, Mannheim, Germany
• anti-CCP2 ELISA, Immunoscan RA, Euro-Diagnostica, Malmoe, Sweden
Rheumatoid factor IgM antibodies
• Nephelometry
• Reuma Latex test, Sclavo diagnostics International, Sovicille, Italy 
• Elia RF IgM, Phadia, Freiburg, Germany
• RF Ab’s: Roche Diagnostics, Mannheim, Germany
• RF IgM, (K6078) Vista 1500, Siemens Healthcare Diagnostics
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on arthritis presentation pattern (and on 
joint erosions) was minimal.
Our results indicate that arthritis in 
ASSD is a heterogeneous condition, 
with different characteristics that are 
linked to the timing of the appearance of 
arthritis. In particular, patients present-
ing ex-novo arthritis during the follow-
up less frequently have laboratory, clini-
cal and radiology features typical of RA, 
suggesting that different mechanisms 
may drive arthritis occurrence in the dif-
ferent phases of ASSD. Another factor 
supporting this hypothesis is that the 
typical accompanying findings of ASSD 
were rare in Group 1 and more common 
in Group 2. As recently suggested by the 
members of the French “Club Rhuma-
tisme and inflammation” (8), we think 
that an overlap between RA and ASSD 
may occur in the first phases of the dis-
ease, whilst a “true” ASSD-related ar-
thritis during the follow-up.
Another interesting observation de-
rived from the evaluation of Group 1 
was that the association between ar-
thritis and ILD was observed in 157 
patients (44% of the group), 56 of them 
(15% of the group) without concomi-
tant myositis. Since ILD frequently 
occurs at RA onset (12), arthritis in 
ASSD is frequently “RA-like” (4, 5, 
8), and ILD is a common manifestation 
of ASSD (2, 3, 13-18), we think that 
some patients diagnosed with RA with 
lung involvement could be in fact not 
diagnosed ASSD. 
The study has some limits. In particu-
lar, the main criticism is related to its 
retrospective design. It is well known 
that these studies are intrinsically as-
sociated with an increased risk of in-
completeness (19, 20). In fact, arthri-
tis serological, radiology and clinical 
data were available in the majority of 
cases but not in all cases. Another po-
tential limitation is that anti-synthetase 
antibodies were assessed using dif-
ferent commercially available kits in 
different centres. Nevertheless, when 
considering these limitations, we have 
to take into account that so far no pro-
spective studies that address ASSD are 
available, and that other multicentre 
studies previously performed had the 
same problems that we have discussed 
(2, 9, 21, 22).  Another bias is that we 
checked only few patients for the newly 
available RA classification criteria (11) 
and not for the new 2010 ACR/EULAR 
classification criteria for RA. This bias 
could be overcome in the incoming pro-
spective part of the AENEAS project. 
Finally, we cannot exclude that some of 
the patients included in Group 1, who 
had an isolated arthritis at disease onset, 
could have presented an asymptomatic 
ILD or myositis. We think that this limi-
tation could be resolved only in the case 
of a very early identification of antisyn-
tethetase antibodies and of a very early 
diagnosis of ASSD. However, we think 
that thanks to the results obtained by 
the AENEAS collaborative group (4, 5) 
and by the French “Club Rhumatisme 
et inflammation” (2, 8, 21) the sensibil-
ity of clinicians in the early diagnosis of 
ASSD in arthritis patients could stead-
ily increase in the next years.  
In conclusion, we have shown that 
heterogeneity is a typical hallmark 
of arthritis in ASSD, that differences 
found in our series may indicate differ-
ent phenotypes of the disease and that 
arthritis pathogenesis in ASSD is com-
plex and potentially different in vari-
ous disease phases.
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